FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

John Teerlink

Research Profile

Disorders

Concepts & Ideas

Procedures

Chemicals & Drugs

Physiology

Hemodynamics

Anatomy

Myocardium

Co-author Network

Publications

TOP 3
Robert J Mentz; Christopher M O'Connor; Randall C Starling; Amanda L Stebbins; John R Teerlink; Dan Atar; Robert M Califf; Justin A Ezekowitz; G Michael Felker; Vic Hasselblad; Gretchen M Heizer; Adrian F Hernandez; Barry M Massie; Piotr Ponikowski
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.
Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Daniel Wojdyla; Robert J Mentz; Marco Metra; Karen Chiswell; John G Cleland; Gad Cotter; Beth A Davison; Mona Fiuzat; Michael M Givertz; George A Mansoor; Barry M Massie
The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction.
John R Teerlink; Scott Thomson; Paul D Varosy; Adriaan A Voors; Denise Wolko; Michael R Zile; Marco Metra; Alan B Miller; Jay P Mohr; Christopher M O'Connor; Ileana L Piña; Piotr Ponikowski; Christina M Salerno; Peter E Carson; John G F Cleland; Gad Cotter; Beth A Davison; Paul Delucca; Howard Dittrich; Michael M Givertz; Paul J Hauptman; Vicente J Iragui; David H Lovett; George A Mansoor; Barry M Massie
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of John Teerlink (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Robert J Mentz; Christopher M O'Connor; Randall C Starling; Amanda L Stebbins; John R Teerlink; Dan Atar; Robert M Califf; Justin A Ezekowitz; G Michael Felker; Vic Hasselblad; Gretchen M Heizer; Adrian F Hernandez; Barry M Massie; Piotr Ponikowski
Predictors of early dyspnoea relief in acute heart failure and the association with 30-day outcomes: findings from ASCEND-HF.
European journal of heart failure 2013;15(4):456-64.
2012: Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Daniel Wojdyla; Robert J Mentz; Marco Metra; Karen Chiswell; John G Cleland; Gad Cotter; Beth A Davison; Mona Fiuzat; Michael M Givertz; George A Mansoor; Barry M Massie
The PROTECT in-hospital risk model: 7-day outcome in patients hospitalized with acute heart failure and renal dysfunction.
European journal of heart failure 2012;14(6):605-12.
2012: John R Teerlink; Scott Thomson; Paul D Varosy; Adriaan A Voors; Denise Wolko; Michael R Zile; Marco Metra; Alan B Miller; Jay P Mohr; Christopher M O'Connor; Ileana L Piña; Piotr Ponikowski; Christina M Salerno; Peter E Carson; John G F Cleland; Gad Cotter; Beth A Davison; Paul Delucca; Howard Dittrich; Michael M Givertz; Paul J Hauptman; Vicente J Iragui; David H Lovett; George A Mansoor; Barry M Massie
The safety of an adenosine A(1)-receptor antagonist, rolofylline, in patients with acute heart failure and renal impairment: findings from PROTECT.
Drug safety : an international journal of medical toxicology and drug experience 2012;35(3):233-44.
2011: Christopher M O'Connor; Piotr Ponikowski; John R Teerlink; Adriaan A Voors; Daniel Bloomfield; John Cleland; Gad Cotter; Beth A Davison; Paul Delucca; Howard C Dittrich; Mona Fiuzat; Kenji Fujita; Michael M Givertz; Gang Jia; Carlo Lombardi; George Mansoor; Barry M Massie; Marco Metra
Impact of serial troponin release on outcomes in patients with acute heart failure: analysis from the PROTECT pilot study.
Circulation. Heart failure 2011;4(6):724-32.
2011: John G F Cleland; Darrel P Francis; Jonathan H Goldman; Barry H Greenberg; Chim C Lang; Jacqueline H Lee; Cyril P Clarke; Jamil Mayet; John J V Mc Murray; Mark Monaghan; Ludwig Neyses; EM Nifontov; Khalil G Saikali; Mitchell Saltzberg; Roxy Senior; Tamaz Shaburishvili; John R Teerlink; Vitaly A Tsyrlin; Scott M Wasserman; Andrew A Wolff; Fady I Malik
The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: a double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial.
Lancet 2011;378(9792):676-83.
2011: John R Teerlink; Rachel Bee; Michael M Chen; Cyril P Clarke; Lyndsey Elliott; Rafael D Escandon; Jonathan H Goldman; Mohammad Reza Habibzadeh; Jacqueline H Lee; Fady I Malik; Khalil G Saikali; Nelson B Schiller; Andrew A Wolff
Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: a first-in-man study.
Lancet 2011;378(9792):667-75.
2011: John R Teerlink
Mind or body: evaluating mind-body therapy efficacy in heart failure trials.
Archives of internal medicine 2011;171(8):758-9.
2011: Mihai Gheorghiade; Peter S Pang; Christopher M O'Connor; Krishna Prasad; John McMurray; John R Teerlink; Mona Fiuzat; Hani N Sabbah; Michel Komajda
Clinical development of pharmacologic agents for acute heart failure syndromes: a proposal for a mechanistic translational phase.
American heart journal 2011;161(2):224-32.
2011: Olga Milo-Cotter; Maurizio Rainisio; Michele Rund; Hengrui Sun; John R Teerlink; Luca Bettari; Silvia Bugatti; Beth Cotter-Davison; Aline Frey; Edo Kaluski; Isaac Kobrin; Carlo Lombardi; John J V McMurray; Marco Metra; Gad Cotter-Davison
Neurohormonal activation in acute heart failure: results from VERITAS.
Cardiology 2011;119(2):96-105.
2010: John R Teerlink
Ivabradine in heart failure--no paradigm SHIFT…yet.
Lancet 2010;376(9744):847-9.
2010: G Michael Felker; Peter S Pang; Kirkwood F Adams; John G F Cleland; Gad Cotter; Kenneth Dickstein; Gerasimos S Filippatos; Gregg C Fonarow; Barry H Greenberg; Adrian F Hernandez; Sadiya Khan; Michel Komajda; Marvin A Konstam; Peter P Liu; Aldo P Maggioni; Barry M Massie; John J McMurray; Mandeep R Mehra; Marco Metra; John O'Connell; Christopher M O'Connor; Ileana L Pina; Piotr Ponikowski; Hani N Sabbah; John R Teerlink; James E Udelson; Clyde W Yancy; Faiez Zannad; Mihai Gheorghiade
Clinical trials of pharmacological therapies in acute heart failure syndromes: lessons learned and directions forward.
Circulation. Heart failure 2010;3(2):314-25.
2010: Olga Milo-Cotter; John R Teerlink; Marco Metra; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Christopher Edwards; Beth D Weatherley; Barry Greenberg; Gerasimos Filippatos; Elaine Unemori; Sam L Teichman; Gad Cotter
Low lymphocyte ratio as a novel prognostic factor in acute heart failure: results from the Pre-RELAX-AHF study.
Cardiology 2010;117(3):190-6.
2009: John R Teerlink; Marco Metra; Valerio Zacà; Hani N Sabbah; Gad Cotter; Mihai Gheorghiade; Livio Dei Cas
Agents with inotropic properties for the management of acute heart failure syndromes. Traditional agents and beyond.
Heart failure reviews 2009;14(4):243-53.
2009: John R Teerlink
A novel approach to improve cardiac performance: cardiac myosin activators.
Heart failure reviews 2009;14(4):289-98.
2009: Peter S Pang; Marvin A Konstam; Holly B Krasa; Karl Swedberg; Faiez Zannad; John E A Blair; Christopher Zimmer; John R Teerlink; Aldo P Maggioni; John C Burnett; Liliana Grinfeld; John Ouyang; James E Udelson; Mihai Gheorghiade
Effects of tolvaptan on dyspnoea relief from the EVEREST trials.
European heart journal 2009;30(18):2233-40.
2009: Mihai Gheorghiade; Kirkwood F Adams; John G F Cleland; Gad Cotter; G Michael Felker; Gerasimos Filippatos; Gregg C Fonarow; Barry H Greenberg; Adrian F Hernandez; Sadiya Khan; Michel Komajda; Marvin A Konstam; Peter P Liu; Aldo P Maggioni; Barry M Massie; John J McMurray; Mandeep Mehra; Marco Metra; John O'Connell; Christopher M O'Connor; Peter S Pang; Ileana L Piña; Hani N Sabbah; John R Teerlink; James E Udelson; Clyde W Yancy; Faiez Zannad; Norman Stockbridge
Phase III clinical trial end points in acute heart failure syndromes: a virtual roundtable with the Acute Heart Failure Syndromes International Working Group.
American heart journal 2009;157(6):957-70.
2009: John R Teerlink; Marco Metra; G Michael Felker; Piotr Ponikowski; Adriaan A Voors; Beth Davison Weatherley; Alon Marmor; Amos Katz; Jacek Grzybowski; Elaine Unemori; Sam L Teichman; Gad Cotter
Relaxin for the treatment of patients with acute heart failure (Pre-RELAX-AHF): a multicentre, randomised, placebo-controlled, parallel-group, dose-finding phase IIb study.
Lancet 2009;373(9673):1429-39.
2008: Jennifer E Ho; John R Teerlink
Role of tolvaptan in acute decompensated heart failure.
Expert review of cardiovascular therapy 2008;6(5):601-8.
2008: Peter S Pang; John G F Cleland; John R Teerlink; Sean P Collins; Christopher J Lindsell; George Sopko; W Frank Peacock; Gregg C Fonarow; Amer Z Aldeen; J Douglas Kirk; Alan Storrow; Miguel Tavares; Alexandre Mebazaa; Edmond Roland; Barrie Massie; Alan S Maisel; Michel Komajda; Gerasimos Filippatos; Mihai Gheorghiade
A proposal to standardize dyspnoea measurement in clinical trials of acute heart failure syndromes: the need for a uniform approach.
European heart journal 2008;29(6):816-24.
2007: john mcmurray; John R Teerlink; Gad Cotter; Robert Bourge; John G F Cleland; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre Amione; Dirk J van Veldhuisen; Jim Lewsey; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Effects of tezosentan on symptoms and clinical outcomes in patients with acute heart failure: the VERITAS randomized controlled trials.
JAMA : the journal of the American Medical Association 2007;298(17):2009-19.
2007: Marina R Bergman; John R Teerlink; Rajeev Mahimkar; Luyi Li; Bo-qing Zhu; Anita Nguyen; Sia Dahi; Joel S Karliner; David H Lovett
Cardiac matrix metalloproteinase-2 expression independently induces marked ventricular remodeling and systolic dysfunction.
American journal of physiology. Heart and circulatory physiology 2007;292(4):H1847-60.
2006: Barry H Greenberg; Mandeep Mehra; John R Teerlink; Paul Ordronneau; David McCollum; Edward M Gilbert
COMPARE: comparison of the effects of carvedilol CR and carvedilol IR on left ventricular ejection fraction in patients with heart failure.
The American journal of cardiology 2006;98(7A):53L-59L.
2006: Milton Packer; William T Abraham; Mandeep Mehra; Clyde W Yancy; Christine E Lawless; Judith E Mitchell; Frank W Smart; Rachel Bijou; Christopher M O'Connor; Barrie Massie; Ileana Pina; Barry H Greenberg; James B Young; Daniel P Fishbein; Paul J Hauptman; Robert Bourge; John E Strobeck; Srinvivas Murali; Douglas Schocken; John R Teerlink; Wayne C Levy; Robin J Trupp; Marc A Silver
Utility of impedance cardiography for the identification of short-term risk of clinical decompensation in stable patients with chronic heart failure.
Journal of the American College of Cardiology 2006;47(11):2245-52.
2006: Bo-qing Zhu; Ursula Simonis; Gary Cecchini; Hui-Zhong Zhou; Luyi Li; John R Teerlink; Joel S Karliner
Comparison of pyrroloquinoline quinone and/or metoprolol on myocardial infarct size and mitochondrial damage in a rat model of ischemia/reperfusion injury.
Journal of cardiovascular pharmacology and therapeutics 2006;11(2):119-28.
2005: John R Teerlink
Overview of randomized clinical trials in acute heart failure syndromes.
The American journal of cardiology 2005;96(6A):59G-67G.
2005: John R Teerlink; john mcmurray; Robert Bourge; John G F Cleland; Gad Cotter; Guillaume Jondeau; Henry Krum; Marco Metra; Christopher M O'Connor; John D Parker; Guillermo Torre Amione; Dirk J van Veldhuisen; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Tezosentan in patients with acute heart failure: design of the Value of Endothelin Receptor Inhibition with Tezosentan in Acute heart failure Study (VERITAS).
American heart journal 2005;150(1):46-53.
2004: Bo-qing Zhu; Hui-Zhong Zhou; John R Teerlink; Joel S Karliner
Pyrroloquinoline quinone (PQQ) decreases myocardial infarct size and improves cardiac function in rat models of ischemia and ischemia/reperfusion.
Cardiovascular drugs and therapy / sponsored by the International Society of Cardiovascular Pharmacotherapy 2004;18(6):421-31.
2004: Madan Sharma; John R Teerlink
A rational approach for the treatment of acute heart failure: current strategies and future options.
Current opinion in cardiology 2004;19(3):254-63.
2003: Guillermo Torre Amione; James B Young; Wilson S Colucci; Basil S. Lewis; Craig Pratt; Gad Cotter; Karl Stangl; Uri Elkayam; John R Teerlink; Aline Frey; Maurizio Rainisio; Isaac Kobrin
Hemodynamic and clinical effects of tezosentan, an intravenous dual endothelin receptor antagonist, in patients hospitalized for acute decompensated heart failure.
Journal of the American College of Cardiology 2003;42(1):140-7.
2003: John R Teerlink; Barrie Massie
Late breaking heart failure trials from the 2003 ACC meeting: EPHESUS and COMPANION.
Journal of cardiac failure 2003;9(3):158-63.
2003: Christopher M O'Connor; Wendy A Gattis; Kirkwood F Adams; Vic Hasselblad; Bleakley Chandler; Aline Frey; Isaac Kobrin; Maurizio Rainisio; Monica R Shah; John R Teerlink; Mihai Gheorghiade
Tezosentan in patients with acute heart failure and acute coronary syndromes: results of the Randomized Intravenous TeZosentan Study (RITZ-4).
Journal of the American College of Cardiology 2003;41(9):1452-7.
2003: Mihai Gheorghiade; Kirkwood F Adams; Wendy A Gattis; John R Teerlink; Cesare Orlandi; Christopher M O'Connor
Surrogate end points in heart failure trials.
American heart journal 2003;145(2 Suppl):S67-70.
2003: Christopher M O'Connor; Wendy A Gattis; John R Teerlink; Kirkwood F Adams; Mihai Gheorghiade
Design considerations and proposed template for clinical trials in hospitalized patients with decompensated chronic heart failure.
American heart journal 2003;145(2 Suppl):S47-50.
2003: John R Teerlink
Dyspnea as an end point in clinical trials of therapies for acute decompensated heart failure.
American heart journal 2003;145(2 Suppl):S26-33.
2002: John R Teerlink
The development of new medical treatments for acute decompensated heart failure.
Heart failure monitor 2002;2(4):129-37.
2000: John R Teerlink; Barrie Massie
The role of beta-blockers in preventing sudden death in heart failure.
Journal of cardiac failure 2000;6(2 Suppl 1):25-33.
1999: John R Teerlink; Barrie Massie
Beta-adrenergic blocker mortality trials in congestive heart failure.
The American journal of cardiology 1999;84(9A):94R-102R.
1998: John R Teerlink; Elyse Foster
Valvular heart disease in pregnancy. A contemporary perspective.
Cardiology clinics 1998;16(3):573-98, x.
1998: John R Teerlink; J M Pfeffer; M A Pfeffer
Effect of left ventricular sphericity on the evolution of ventricular dysfunction in rats with diffuse isoproterenol-induced myocardial necrosis.
Journal of cardiac failure 1998;4(1):45-56.
1994: John R Teerlink; J M Pfeffer; M A Pfeffer
Progressive ventricular remodeling in response to diffuse isoproterenol-induced myocardial necrosis in rats.
Circulation research 1994;75(1):105-13.